Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • From the Analyst's Couch
  • Published:

Rheumatoid arthritis market

Nature Reviews Drug Discovery volume 8, pages 693–694 (2009)Cite this article

Rheumatoid arthritis (RA) is a chronic, systemic inflammatory disease that affects ∼0.8% of the adult population worldwide. Onset typically occurs between 30 and 50 years of age, with an estimated incidence in the United States of 25 per 100,000 persons for men and 54 per 100,000 persons for women.

Three TNF inhibitors are well established in the RA market, as well as for several other immuno-inflammatory disorders. Infliximab (Remicade; Centocor Ortho Biotech/Schering-Plough), a chimeric monoclonal antibody (mAb) that is specific for TNF, and the fusion protein etanercept (Enbrel; Amgen/Wyeth), which contains the ligand-binding portion of the soluble TNF receptor, have been approved for RA for about a decade. The fully human TNF-specific mAb adalimumab (Humira; Abbott) was approved for the treatment of RA in 2002.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Rheumatoid arthritis (RA) market.

References

  1. Bongartz, T. et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systemic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295, 2275–2285 (2006).

    Article  CAS  Google Scholar 

  2. Saag, K. G. et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 59, 762–784 (2008).

    Article  CAS  Google Scholar 

  3. Breedveld, F. C. et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 54, 26–37 (2006).

    Article  CAS  Google Scholar 

  4. Smolen, J. S. et al. Active-controlled study of patients receiving infliximab for the treatment of rheumatoid arthritis of early onset (ASPIRE) study group. Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial. Arthritis Rheum. 54, 702–710 (2006).

    Article  CAS  Google Scholar 

  5. Klareskog, L. et al. Therapeutic effects of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomized controlled trial. Lancet 363, 675–681 (2004).

    Article  CAS  Google Scholar 

  6. Weinblatt, M. et al. Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and non-biologic disease-modifying antirheumatic drugs. Arthritis Rheum. 54, 2807–2816 (2006).

    Article  CAS  Google Scholar 

  7. Kremer, J. M. et al. The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690550 versus placebo. Arthritis Rheum. 60, 1895–1905 (2009).

    Article  CAS  Google Scholar 

  8. Weinblatt, M. E. et al. Treatment of rheumatoid arthritis with a Syk kinase inhibitor: a twelve-week, randomized, placebo-controlled trial. Arthritis Rheum. 58, 3309–3318 (2008).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Jeffrey G. Stoll and Uma Yasothan are at IMS Health, 7 Harewood Avenue, London, NW1 6JB, UK. JStoll@us.imshealth.com; UYasothan@de.imshealth.com,

    Jeffrey G. Stoll & Uma Yasothan

  2. UYasothan@de.imshealth.com,

    Jeffrey G. Stoll & Uma Yasothan

Authors
  1. Jeffrey G. Stoll
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Uma Yasothan
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Stoll, J., Yasothan, U. Rheumatoid arthritis market. Nat Rev Drug Discov 8, 693–694 (2009). https://doi.org/10.1038/nrd2947

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd2947

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing